Logo image of CNS

COHEN & STEERS INC (CNS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock

70.42 USD
+0.79 (+1.13%)
Last: 1/16/2026, 8:04:00 PM
70.42 USD
0 (0%)
After Hours: 1/16/2026, 8:04:00 PM
Fundamental Rating

6

Taking everything into account, CNS scores 6 out of 10 in our fundamental rating. CNS was compared to 238 industry peers in the Capital Markets industry. CNS scores excellent on profitability, but there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • CNS had positive earnings in the past year.
  • CNS had a negative operating cash flow in the past year.
  • In the past 5 years CNS has always been profitable.
  • In the past 5 years CNS always reported a positive cash flow from operatings.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1.2 Ratios

  • With an excellent Return On Assets value of 20.48%, CNS belongs to the best of the industry, outperforming 97.48% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 29.83%, CNS belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 24.24%, CNS belongs to the top of the industry, outperforming 97.90% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.27%.
  • The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROIC 24.24%
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 29.73%, CNS is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNS has declined.
  • CNS's Operating Margin of 33.83% is fine compared to the rest of the industry. CNS outperforms 65.13% of its industry peers.
  • In the last couple of years the Operating Margin of CNS has declined.
  • CNS has a better Gross Margin (88.60%) than 92.86% of its industry peers.
  • In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
Industry RankSector Rank
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CNS has been increased compared to 1 year ago.
  • Compared to 5 years ago, CNS has more shares outstanding
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 9.78 indicates that CNS is not in any danger for bankruptcy at the moment.
  • CNS has a better Altman-Z score (9.78) than 94.12% of its industry peers.
  • There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.78
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

  • CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.79, CNS is doing worse than 63.45% of the companies in the same industry.
  • A Quick Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.79, CNS is not doing good in the industry: 63.03% of the companies in the same industry are doing better.
  • CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 8.87% over the past year.
  • Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
  • The Revenue has grown by 11.13% in the past year. This is quite good.
  • CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%

3.2 Future

  • Based on estimates for the next years, CNS will show a small growth in Earnings Per Share. The EPS will grow by 7.68% on average per year.
  • CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.21% yearly.
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

2

4. Valuation

4.1 Price/Earnings Ratio

  • CNS is valuated rather expensively with a Price/Earnings ratio of 22.94.
  • 62.60% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.38. CNS is around the same levels.
  • With a Price/Forward Earnings ratio of 20.47, CNS is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 24.29. CNS is around the same levels.
Industry RankSector Rank
PE 22.94
Fwd PE 20.47
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • CNS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CNS is cheaper than 77.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.62
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.03
PEG (5Y)9.18
EPS Next 2Y8.37%
EPS Next 3Y8.1%

4

5. Dividend

5.1 Amount

  • CNS has a Yearly Dividend Yield of 3.56%.
  • Compared to an average industry Dividend Yield of 6.10, CNS has a dividend in line with its industry peers.
  • CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 3.56%

5.2 History

  • The dividend of CNS decreases each year by -7.12%.
  • CNS has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

COHEN & STEERS INC

NYSE:CNS (1/16/2026, 8:04:00 PM)

After market: 70.42 0 (0%)

70.42

+0.79 (+1.13%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-16
Earnings (Next)01-22
Inst Owners58.73%
Inst Owner Change-0.05%
Ins Owners22.81%
Ins Owner Change3.32%
Market Cap3.59B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (11.53%)
Short Float %6.31%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 3.56%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.35%
PT rev (3m)-1.28%
EPS NQ rev (1m)-1.21%
EPS NQ rev (3m)1.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE 22.94
Fwd PE 20.47
P/S 6.51
P/FCF N/A
P/OCF N/A
P/B 6.53
P/tB 6.77
EV/EBITDA 17.62
EPS(TTM)3.07
EY4.36%
EPS(NY)3.44
Fwd EY4.89%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)5.03
PEG (5Y)9.18
Graham Number27.3
Profitability
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROCE 31.59%
ROIC 24.24%
ROICexc 29.06%
ROICexgc 32.58%
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
FCFM N/A
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 63.99%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z 9.78
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.2%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.


Can you provide the financial health for CNS stock?

The financial health rating of COHEN & STEERS INC (CNS) is 6 / 10.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.